On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- Finance Minister Pushed for All-Product Re-Pricing in 2021: CEFP Minutes
December 3, 2020
- Chuikyo Reps Raise No Opposition to Off-Year Re-Pricing, Still Split over Product Scope
December 3, 2020
- MHLW to Issue Notification to Urge Drug Makers’ Prompt Info Provisioning on Supply Shortages
December 3, 2020
- Japan Diet Clears Immunization Bill
December 2, 2020
- Japan’s Volume-Based Generic Share 78.3% in September, Fails to Hit Govt Goal
December 2, 2020
- Average NHI-Market Price Gap at 8.0%: MHLW
December 2, 2020
- Japan’s Healthcare Spend Rises to 43.4 Trillion Yen in FY2018
December 2, 2020
- MHLW Approves Label Expansions for Forxiga, Trelegy, Evrenzo, Cabometyx and More
November 30, 2020
- Ono’s Cancer Cachexia Drug to Finally Come Up for PAFSC Review on Dec. 11
November 30, 2020
- MHLW Says 7,500 Vaccine Freezers for Storage at Minus 20 Degrees C, Presumably for Moderna Shot
November 30, 2020
- CEFP Member Urges Off-Year Re-Pricing for Preferably All Products, At Least 80%
November 30, 2020
- Japan to Set New Generic Target by March-End: Health Minister
November 30, 2020
- ICH to Stick to Urgent Topics with Significant Impact for Now amid COVID-19
November 30, 2020
- Orphan Drug Status Granted for Lilly’s Selpercatinib, 6 More APIs
November 27, 2020
- Japan Diet Expected to Enact Immunization Bill on Dec. 2
November 27, 2020
- COVID-19 Vaccines Not Actively Recommended for Children: Professor
November 27, 2020
- Second CAR-T Therapy Yescarta Up for Panel Review; MHLW to Report Corrective Measures for Zolgensma Issue
November 27, 2020
- LDP Health Policy Clique Set to Urge Govt to Skip Off-Year Re-Pricing Next Year, but Explore Middle Ground at Same Time
November 27, 2020
- PM Says to Get COVID-19 Shot When His Turn Comes Around
November 26, 2020
- MOF Panel Issues FY2021 Budget Recommendation, Ups Tone on All-Product Drug Re-Pricing
November 26, 2020
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…